Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

NCT06225596 is registered in ClinicalTrials.gov with BicycleTx Limited as lead sponsor.

NCT NCT06225596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06225596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Lead sponsor
BicycleTx Limited
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 24, 2024
Completion date
March 31, 2028
Enrollment
375 (estimated)
Sites
102

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic urothelial cancer